SCHEMBL3228422

SCHEMBL3228422

CCc1ccccc1-n1ccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.58
CYP3A4 P08684 7/20 0.53
CYP1A2 P05177 5/20 0.53
CYP2D6 P10635 5/20 0.53
CYP2C19 P33261 5/20 0.53
CYP2C9 P11712 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
TDP1 Q9NUW8 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
LMNA P02545 2/20 0.53
MAPK1 P28482 1/20 0.53
PMP22 Q01453 1/20 0.53
GAA P10253 1/20 0.50
HTR5A P47898 1/20 0.49
CYP11B1 P15538 3/20 0.47
CYP11B2 P19099 3/20 0.47
CYP19A1 P11511 3/20 0.47
ALOX15 P16050 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26731495 0.88 IDO1 (0.53) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL28150537 0.85 IDO1 (0.50) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL8586698 0.84 IDO1 (0.49) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL3005570 0.84 IDO1 (0.49) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL8436958 0.84 IDO1 (0.61) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2463222 0.84 IDO1 (0.56) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL8619287 0.83 IDO1 (0.51) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL26728947 0.83 IDO1 (0.51) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL20155667 0.82 CYP19A1 (0.47) IDO1CYP3A4CYP1A2CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL27626083 0.82 IDO1 (0.54) IDO1CYP3A4CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104324585-A Method for purifying blast furnace flue gas by using ionic liquid ZHU ZHONGLIANG 2015-02-04 CN claimed
CN-101484453-A Derivatives of imidazo [1, 2-alpha ] pyridine-2-carboxamides, their preparation and their use in therapy SANOFI AVENTIS (FR) 2009-07-15 CN claimed
US-12006308-B2 Adhesive composition for semiconductor circuit connection and adhesive film containing the same LG CHEM, LTD. (KR) 2024-06-11 US disclosed
US-20210115021-A1 ADHESIVE COMPOSITION FOR SEMICONDUCTOR CIRCUIT CONNECTION AND ADHESIVE FILM CONTAINING THE SAME LG CHEM, LTD. (KR) 2021-04-22 US disclosed
CN-104324585-A Method for purifying blast furnace flue gas by using ionic liquid ZHU ZHONGLIANG 2015-02-04 CN disclosed
CN-104324585-A Method for purifying blast furnace flue gas by using ionic liquid ZHU ZHONGLIANG 2015-02-04 CN disclosed
CN-101484453-B Derivatives of imidazo [1, 2-alpha ] pyridine-2-carboxamides, their preparation and their use in therapy SANOFI AVENTIS 2012-07-04 CN disclosed
WO-2010141696-A1 METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES DARA BIOSCIENCES, INC. (US) 2010-12-09 WO disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed
CN-101484453-A Derivatives of imidazo [1, 2-alpha ] pyridine-2-carboxamides, their preparation and their use in therapy SANOFI AVENTIS (FR) 2009-07-15 CN disclosed
EP-0003560-B1 IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS THE WELLCOME FOUNDATION LIMITED (GB) 1984-05-02 EP disclosed
US-4431815-A CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS BURROUGHS WELLCOME CO. (US) 1984-02-14 US disclosed
EP-0003560-A2 Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations THE WELLCOME FOUNDATION LIMITED (GB) 1979-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12006308-B2 Adhesive composition for semiconductor circuit connection and adhesive film containing the same ASH2L, SMARCC1, SMARCC2 IDO1 2926/4885CYP3A4 3501/4885CYP1A2 3943/4885
US-20210115021-A1 ADHESIVE COMPOSITION FOR SEMICONDUCTOR CIRCUIT CONNECTION AND ADHESIVE FILM CONTAINING THE SAME ASH2L, SMARCC1, SMARCC2 IDO1 2926/4885CYP3A4 3501/4885CYP1A2 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.